iFAST Diagnostics

iFAST Diagnostics is a pioneering company in the medical diagnostics sector, specializing in rapid antimicrobial susceptibility testing (AST). The company addresses the critical issue of antibiotic resistance, which has become increasingly unpredictable and severe, with resistance levels ranging from 20% to 98%. Traditional AST methods take 48 to 72 hours to deliver results, during which patients' conditions can deteriorate. iFAST Diagnostics offers a groundbreaking solution with its proprietary technology, delivering results in just 4 hours for urine samples and 8 hours for sepsis cases. This rapid turnaround not only saves lives but also helps in reducing the spread of antimicrobial resistance.

The company operates primarily in the healthcare market, serving hospitals, clinics, and laboratories that require quick and accurate diagnostic solutions. iFAST Diagnostics employs a business-to-business (B2B) model, generating revenue through the sale of its diagnostic systems and associated consumables. The company is poised to launch its research system in 2023, with a clinical system expected to follow in 2024.

The leadership team at iFAST Diagnostics brings a wealth of experience in biomedical engineering, microfluidics, and lab-on-a-chip technology. Key figures include Dr. Toby King, CEO, who has over 25 years of experience in building and running early-stage medtech companies, and Prof. Mark, the acting CSO, who is also a Scientific Leader at UKHSA Porton Down and a Professor for Antimicrobial Therapy at College London.

Keywords: antimicrobial susceptibility testing, rapid diagnostics, antibiotic resistance, healthcare, medical technology, microfluidics, lab-on-a-chip, sepsis, urine samples, B2B.